Aurobindo Pharma Ltd.

NSE: AUROPHARMA BSE: 524804 SECTOR: Pharmaceuticals & Drugs  125k   1k   243

467.35
+0.75 (0.16%)
NSE: Today, 03:58 PM

Price Summary

Today's High

₹ 470.95

Today's Low

₹ 464

52 Week High

₹ 742

52 Week Low

₹ 455.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

27383.84 Cr.

Enterprise Value

29151.68 Cr.

No. of Shares

58.59 Cr.

P/E

20.61

P/B

1.6

Face Value

₹ 1

Div. Yield

1.92 %

Book Value (TTM)

₹  292.59

CASH

50.78 Cr.

DEBT

1818.62 Cr.

Promoter Holding

51.83 %

EPS (TTM)

₹  22.68

Sales Growth

-28.67%

ROE

8.81 %

ROCE

8.52%

Profit Growth

-53.27 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Aurobindo Pharma Ltd.

Molnaflu Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR

Index Presence

The company is present in 31 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-28.67%
3 Year-2.71%
5 Year3.28%

Profit Growth

1 Year-53.27%
3 Year-1.66%
5 Year-3.15%

ROE%

1 Year8.81%
3 Year15.22%
5 Year15.94%

ROCE %

1 Year8.52%
3 Year15.85%
5 Year16.29%

Debt/Equity

0.1062

Price to Cash Flow

7.35

Interest Cover Ratio

97.6635182998819

CFO/PAT (5 Yr. Avg.)

1.06007050168591

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2022 51.83 14.92
Jun 2022 51.83 14.97
Mar 2022 51.83 14.05
Dec 2021 51.83 22.97
Sep 2021 51.83 22.98
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 2134.69 Cr.
  • Company has a healthy Interest coverage ratio of 97.6635182998819.
  • The Company has been maintaining an effective average operating margins of 20.8731194163245% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 2.35235124863369.
  • The company has a good cash flow management; CFO/PAT stands at 1.06007050168591.

 Limitations

  • The company has shown a poor profit growth of -1.66218670284374% for the Past 3 years.
  • The company has shown a poor revenue growth of -2.71271940373218% for the Past 3 years.
  • Tax rate is low at 11.1616630432127.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
Net Sales 2883.18 2623.05 2887.17 2786.92 3025.66
Total Expenditure 2543.45 2407.14 2380.2 2544.66 2729.76
Operating Profit 339.73 215.91 506.97 242.26 295.9
Other Income 82.37 131.29 413.37 38.71 55.86
Interest 3.44 3.54 4.91 7.85 19.2
Depreciation 98.18 101.2 101.22 103.05 108.8
Exceptional Items 0 0 -74.71 0 0
Profit Before Tax 320.48 242.46 739.5 170.07 223.76
Tax 122.8 2.65 -62.66 47.91 59.13
Profit After Tax 197.68 239.81 802.16 122.16 164.63
Adjusted EPS (Rs) 3.37 4.09 13.69 2.09 2.81

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 10269.9 12257.89 13370.77 15823.68 11287.14
Total Expenditure 7599.89 9848.6 10672.9 11703.85 9831.6
Operating Profit 2670.01 2409.29 2697.87 4119.83 1455.54
Other Income 80.65 199.22 388.79 589.86 688.85
Interest 52.89 230.86 243.28 28.68 16.94
Depreciation 354.83 413.03 473.33 488 415.26
Exceptional Items 0 0 0 0 -74.71
Profit Before Tax 2342.94 1964.62 2370.05 4193.01 1637.48
Tax 530.17 434.89 493.17 1080.1 182.77
Net Profit 1812.77 1529.73 1876.88 3112.91 1454.71
Adjusted EPS (Rs.) 30.94 26.11 32.03 53.13 24.83

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 58.59 58.59 58.59 58.59 58.59
Total Reserves 9923.99 11292.03 12993.91 15866.02 17058.75
Borrowings 0 0 0 0 0
Other N/C liabilities 57.08 53.64 138.86 1412.13 682.34
Current liabilities 5754.18 6736.46 6372.25 6756.58 4180.97
Total Liabilities 15793.84 18140.72 19563.61 24093.32 21980.65
Assets
Net Block 3392.97 4149.7 4417.8 4472.07 3585.83
Capital WIP 1100.23 750.07 814.85 719.02 225.15
Intangible WIP 43.75 38.94 0 15.87 0
Investments 1967.48 2339.04 2527.39 4880.89 6584.35
Loans & Advances 207.66 402.93 444.9 1610.41 1603
Other N/C Assets 100.55 51.7 70.37 59.05 147.21
Current Assets 8981.2 10408.34 11288.3 12336.01 9835.11
Total Assets 15793.84 18140.72 19563.61 24093.32 21980.65
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 2342.94 1964.62 2370.05 4193.01 1637.48
Adjustment 329.16 458.99 414.2 53.15 -30.65
Changes in Assets & Liabilities -1219.73 -1411.6 -204.18 -624.78 2811.95
Tax Paid -529.97 -482.12 -378.69 -626.85 -692.07
Operating Cash Flow 922.4 529.89 2201.38 2994.53 3726.71
Investing Cash Flow -990.6 -1300.54 -948.08 -2650.24 -1614.54
Financing Cash Flow 439.69 599.4 -1254.65 -28.06 -2447.54
Net Cash Flow 371.49 -171.25 -1.35 316.23 -335.37

Corporate Actions

Investors Details

PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022% Sep 2022%
Promoters 51.83 51.83 51.83 51.83 51.83
rpr sons advisors ... 33.51 33.51 33.51 33.51 33.51
k nityananda reddy 4.33 4.33 4.33 4.33 4.33
k nityananda reddy - - - - -
kambam kirthi reddy - - - - -
kirthi reddy kambam 3.49 3.49 3.49 3.49 3.49
venkata ramprasad ... 3.07 3.07 3.07 3.07 3.07
axis clinicals lim... 0.11 0.11 0.11 0.11 0.11
axis clinicals lim... 2.85 2.85 2.85 2.85 2.85
m sivakumaran 2.47 2.47 2.47 2.47 2.47
kambam spoorthi 1.19 1.19 - 1.19 1.19
k spoorthi - - 1.19 - -
k rajeswari - - 0.31 - -
rajeswari kambam - - - - 0.31
kottamanchi rajes... 0.31 0.31 - 0.31 -
m sumanth kumar re... 0.27 0.27 0.27 0.27 0.27
trident chemphar l... 0.13 0.13 0.13 0.13 0.13
prasada reddy kamb... 0.05 0.05 0.05 0.05 0.05
penaka neha reddy - - - - -
suneela rani penaka 0.02 0.02 0.02 0.02 0.02
PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022% Sep 2022%
Investors 48.17 48.17 48.17 48.17 48.17
hdfc trustee co lt... - - - - -
hdfc trustee compa... - - - - -
life insurance cor... 4.34 5.33 5.48 5.48 5.48
hdfc trustee compa... - - - - -
hdfc trustee compa... - - 3.82 - -
hdfc trustee compa... - 3.59 - - -
hdfc large and mid... - - - 3.49 -
hdfc trustee compa... - - - - 3.05
qualified institut... - - - - -
mirae asset emergi... - - 1.42 - 1.93
mirae asset tax sa... - - - 1.79 -
nippon life india ... - 1.39 - - -
nippon life india ... - - 1.13 - -
reliance capital t... - - - - -
bnp paribas arbitr... - - - - -
nippon life india ... 1.26 - - - -
bnp paribas arbitr... 1.22 1.15 1.19 1.12 1.19
saudi arabian mone... - - - - -
icici prudential l... - - - - -
iepf 0.13 0.13 0.13 0.12 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Aurobindo Pharma informs about disclosure26 Nov 2022, 12:20PM Aurobindo Pharma informs about press release23 Nov 2022, 12:45PM Aurobindo Pharma’s arm enters into license agreement with Evive Biotech23 Nov 2022, 12:26PM Aurobindo Pharma aiming to complete Pen G plant in Andhra Pradesh by March 202422 Nov 2022, 3:30PM Aurobindo Pharma informs about completion of US FDA inspection at unit IX 19 Nov 2022, 2:56PM USFDA concludes inspection at Aurobindo Pharma’s Telangana facility19 Nov 2022, 12:45PM Aurobindo Pharma informs about analyst meet18 Nov 2022, 1:03PM Aurobindo Pharma’s arm receives USFDA approval for Amphotericin B Liposome for Injection.18 Nov 2022, 10:58AM Aurobindo Pharma informs about press release18 Nov 2022, 10:32AM Aurobindo Pharma gets EIR from USFDA for manufacturing facility in Andhra Pradesh17 Nov 2022, 10:37AM Aurobindo Pharma reports 41% fall in Q2 consolidated net profit14 Nov 2022, 11:59AM Aurobindo Pharma - Quaterly Results12 Nov 2022, 5:31PM Aurobindo Pharma - Quaterly Results12 Nov 2022, 5:31PM Aurobindo Pharma - Quaterly Results12 Nov 2022, 5:31PM Aurobindo Pharma informs about disclosure10 Nov 2022, 3:27PM Aurobindo Pharma’s unit recalling 88,080 vials of Tranexamic acid injection25 Oct 2022, 10:27AM Aurobindo Pharma’s arm receives EIR for Raleigh plant 22 Sep 2022, 11:42AM Aurobindo Pharma’s arm gets nod to expand mammalian cell culture manufacturing facility2 Sep 2022, 11:20AM Aurobindo Pharma informs about completion of US FDA inspection at raleigh plant 29 Aug 2022, 4:18PM USFDA completes inspection at Aurobindo Pharma’s Raleigh unit with 1 observation29 Aug 2022, 12:48PM Aurobindo Pharma informs about disclosure 26 Aug 2022, 10:12AM Aurobindo Pharma’s arm gets nod to manufacture, market Medroxyprogesterone Acetate Injectable Suspension 24 Aug 2022, 10:38AM Aurobindo Pharma informs about press release24 Aug 2022, 10:38AM Aurobindo Pharma acquires 51% stake in GLS Pharma18 Aug 2022, 11:15AM Aurobindo Pharma’s arm receives USFDA’s approval for Vasopressin Injection16 Aug 2022, 9:53AM Aurobindo Pharma informs about the press releaseinforms about the press release16 Aug 2022, 9:46AM Aurobindo Pharma reports 32% fall in Q1 consolidated net profit12 Aug 2022, 12:07PM Aurobindo Pharma - Quaterly Results11 Aug 2022, 5:58PM Aurobindo Pharma - Quaterly Results11 Aug 2022, 5:58PM Aurobindo Pharma - Quaterly Results11 Aug 2022, 5:58PM USFDA completes inspection at Unit VII of Aurobindo Pharma5 Aug 2022, 2:48PM Aurobindo Pharma informs about proceedings of AGM 3 Aug 2022, 3:45PM Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit3 Aug 2022, 10:50AM Aurobindo Pharma informs about press release6 Jul 2022, 3:17PM Aurobindo Pharma’s arm gets USFDA nod for Triamcinolone Acetonide injectable suspension6 Jul 2022, 2:39PM Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare5 Jul 2022, 9:59AM Aurobindo Pharma gets warning letter from SEBI 27 Jun 2022, 4:58PM Aurobindo Pharma informs about disclosure 27 Jun 2022, 3:39PM Aurobindo Pharma gets nod to acquire 51% stake in GLS Pharma20 Jun 2022, 10:45AM Aurobindo Pharma informs about investors conference18 Jun 2022, 12:51PM Aurobindo Pharma informs about press release 7 Jun 2022, 1:02PM Aurobindo Pharma’s arm gets USFDA approval for Leuprolide Acetate injection7 Jun 2022, 12:07PM Aurobindo Pharma reports 28% fall in Q4 consolidated net profit2 Jun 2022, 12:47PM Aurobindo Pharma - Quaterly Results30 May 2022, 7:44PM Aurobindo Pharma - Quaterly Results30 May 2022, 7:44PM Aurobindo Pharma’s arm gets USFDA’s final approval for Pemetrexed for Injection 26 May 2022, 12:16PM Aurobindo Pharma informs about press release26 May 2022, 11:56AM Aurobindo Pharma gets 6 observations from USFDA for Unit VII11 May 2022, 9:46AM Aurobindo Pharma’s arm gets USFDA approval for Bortezomib for injection4 May 2022, 9:19AM Aurobindo Pharma’s unit recalls Cyanocobalamin Injection in US market25 Apr 2022, 9:28AM

Aurobindo Pharma Stock Price Analysis and Quick Research Report. Is Aurobindo Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 3726.71 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.1062 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was -53.2685618779456 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 12.8955607886497 % which is a bad sign for profitability.
     
  • ROE: Aurobindo Pharma have a poor ROE of 8.80524691535502 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Aurobindo Pharma

X